公开(公告)号：EP1853583B1

公开(公告)日：2011-09-07

申请号：EP06735089.2

申请日：2006-02-14

申请人： Schering Corporation ,  Pharmacopeia, LLC

发明人： WONG, Michael K. C. ,  SHU, Youheng ,  YU, Wensheng ,  ROSENBLUM, Stuart B. ,  KOZLOWSKI, Joseph A. ,  MCGUINNESS, Brian F. ,  SHAO, Yuefei ,  HOBBS, Douglas W.

IPC分类号： C07D401/12 ,  C07D409/14 ,  C07D401/14 ,  C07D405/14 ,  C07D211/58 ,  C07D417/14 ,  C07D413/14 ,  A61K31/497 ,  A61P31/00 ,  A61P29/00

CPC分类号： C07D401/14 ,  C07D211/58 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formual should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

公开(公告)号：EP2094688A1

公开(公告)日：2009-09-02

申请号：EP07863159.5

申请日：2007-12-20

申请人： Schering Corporation ,  Pharmacopeia, Inc.

发明人： ZENG, Qingbei ,  ROSENBLUM, Stuart B. ,  KOZLOWSKI, Joseph A. ,  SHIH, Neng-Yang ,  MCGUINNESS, Brian F. ,  HOBBS, Douglas W.

IPC分类号： C07D401/14 ,  A61K31/495 ,  A61P29/00

CPC分类号： C07D401/14

摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or Formula 5: [Chemical formulas should be inserted here as they appear on abstract in paper form.] or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

公开(公告)号：EP2318388A2

公开(公告)日：2011-05-11

申请号：EP09775391.7

申请日：2009-07-21

申请人： Schering Corporation

发明人： MCCORMICK, Kevin D. ,  ASLANIAN, Robert G. ,  MANGIARACINA, Pietro ,  BERLIN, Michael Y. ,  DE LERA RUIZ, Manuel ,  BOYCE, Christopher W ,  CHAO, Jianhua ,  TING, Pauline C. ,  ZHENG, Junying ,  ROSENBLUM, Stuart B.

IPC分类号： C07D401/06

CPC分类号： C07D471/10 ,  C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D491/107 ,  C07D491/20 ,  C07D495/20 ,  C07D498/10

摘要： The present invention relates to novel Tricyclic Spirocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Spirocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disoder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

摘要翻译： 本发明涉及新的三环螺环衍生物，包含三环螺环衍生物的药物组合物以及这些化合物用于治疗或预防过敏症，过敏引起的气道反应，充血，心血管疾病，炎性疾病，胃肠道病症， 神经系统疾病，代谢疾病，肥胖或肥胖相关疾病，糖尿病，糖尿病并发症，葡萄糖耐量降低或空腹血糖受损。

公开(公告)号：EP2222672A1

公开(公告)日：2010-09-01

申请号：EP08850408.9

申请日：2008-11-13

申请人： Schering Corporation

发明人： CHEN, Kevin X. ,  ROSENBLUM, Stuart B. ,  NJOROGE, F. George ,  KOZLOWSKI, Joseph A.

IPC分类号： C07D417/14 ,  A61K31/67 ,  A61P31/12

CPC分类号： C07D417/14

摘要： The present invention relates to 3-Aminosulfonyl Substituted Indole Derivatives, compositions comprising at least one 3-Aminosulfonyl Substituted Indole Derivative, and methods of using the 3-Aminosulfonyl Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.

摘要翻译： 本发明涉及3-氨基磺酰基取代的吲哚衍生物，包含至少一种3-氨基磺酰基取代的吲哚衍生物的组合物，以及使用3-氨基磺酰基取代的吲哚衍生物治疗或预防病毒感染或病毒相关病症的方法 患者。

公开(公告)号：EP2064180A1

公开(公告)日：2009-06-03

申请号：EP07862998.7

申请日：2007-12-17

申请人： Schering Corporation

发明人： CHEN, Kevin X. ,  VENKATRAMAN, Srikanth ,  NJOROGE, F., George ,  ROSENBLUM, Stuart B. ,  LESBURG, Charles A. ,  DUCA, Jose S. ,  SHIH, Neng-Yang ,  VELAZQUEZ, Francisco ,  ANILKUMAR, Gopinadhan N. ,  ZENG, Qingbei ,  KOZLOWSKI, Joseph A.

IPC分类号： C07D209/60 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D471/04 ,  C07D491/04 ,  A61K31/407 ,  A61P31/12 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D491/04 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

摘要： The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl, cyclopentenyl, 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl or 5-membered heteroaryl ring.

公开(公告)号：EP1853583A1

公开(公告)日：2007-11-14

申请号：EP06735089.2

申请日：2006-02-14

申请人： Schering Corporation ,  PHARMACOPEIA, INC.

发明人： WONG, Michael K. C. ,  SHU, Youheng ,  YU, Wensheng ,  ROSENBLUM, Stuart B. ,  KOZLOWSKI, Joseph A. ,  MCGUINNESS, Brian F. ,  SHAO, Yuefei ,  HOBBS, Douglas, W.

IPC分类号： C07D401/12 ,  C07D409/14 ,  C07D401/14 ,  C07D405/14 ,  C07D211/58 ,  C07D417/14 ,  C07D413/14 ,  A61K31/497 ,  A61P31/00 ,  A61P29/00

CPC分类号： C07D401/14 ,  C07D211/58 ,  C07D401/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formual should be inserted here as it appears on the abstract in paper form. and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.